Szpechcinski, A.; Moes-Sosnowska, J.; Skronska, P.; Lechowicz, U.; Pelc, M.; Szolkowska, M.; Rudzinski, P.; Wojda, E.; Maszkowska-Kopij, K.; Langfort, R.;
et al. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer. Int. J. Mol. Sci. 2024, 25, 7908.
https://doi.org/10.3390/ijms25147908
AMA Style
Szpechcinski A, Moes-Sosnowska J, Skronska P, Lechowicz U, Pelc M, Szolkowska M, Rudzinski P, Wojda E, Maszkowska-Kopij K, Langfort R,
et al. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences. 2024; 25(14):7908.
https://doi.org/10.3390/ijms25147908
Chicago/Turabian Style
Szpechcinski, Adam, Joanna Moes-Sosnowska, Paulina Skronska, Urszula Lechowicz, Magdalena Pelc, Malgorzata Szolkowska, Piotr Rudzinski, Emil Wojda, Krystyna Maszkowska-Kopij, Renata Langfort,
and et al. 2024. "The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer" International Journal of Molecular Sciences 25, no. 14: 7908.
https://doi.org/10.3390/ijms25147908
APA Style
Szpechcinski, A., Moes-Sosnowska, J., Skronska, P., Lechowicz, U., Pelc, M., Szolkowska, M., Rudzinski, P., Wojda, E., Maszkowska-Kopij, K., Langfort, R., Orlowski, T., Sliwinski, P., Polaczek, M., & Chorostowska-Wynimko, J.
(2024). The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences, 25(14), 7908.
https://doi.org/10.3390/ijms25147908
